Hematology & Internal Medicine & Family Medicine
Platelet count
Platelets—also known as thrombocytes—are small, anucleated cell fragments produced by megakaryocytes in the bone marrow through cytoplasmic fragmentation. Their primary function is to ensure primary hemostasis: they adhere to the exposed subendothelium of a damaged blood vessel (via von Willebrand factor and subendothelial collagen), activate, and aggregate to form a platelet plug that stops bleeding within minutes. Platelet count—measured by hematology analyzers as part of a complete blood count (CBC)—expresses the concentration of platelets per microliter (µL) or per liter (× 10⁹/L) of circulating blood. Normal values in healthy adults range from 150 to 400 × 10⁹/L (or 150,000 to 400,000/µL), with a platelet lifespan of 7 to 10 days in circulation before being cleared by splenic and hepatic macrophages. The two main quantitative platelet abnormalities are thrombocytopenia (platelets below 150 × 10⁹/L), which carries a bleeding risk depending on severity, and thrombocytosis (platelets above 450 × 10⁹/L), which may reflect a benign reaction to an inflammatory process or a myeloproliferative neoplasm (essential thrombocythemia) requiring treatment to prevent thrombotic complications. EDTA-dependent pseudothrombocytopenia—a laboratory artifact caused by autoantibodies inducing platelet aggregation in vitro in the EDTA anticoagulant tube—is a common and benign cause of apparent thrombocytopenia that must be excluded by checking a citrate tube or a blood smear before any invasive assessment or therapeutic decision.
Reference values and clinical thresholds
| Value | Platelets (× 10⁹/L) | Clinical significance |
|---|---|---|
| Normal values | 150 to 400 × 10⁹/L | Normal primary hemostasis + no platelet-related bleeding risk |
| Mild thrombocytopenia | 100 to 150 x 10^9/L | Clinically negligible bleeding risk in daily life + monitoring according to etiology + no contraindication to common invasive procedures |
| Mild thrombocytopenia | 50 to 100 x 10⁹/L | Increased risk of bleeding with trauma or invasive procedures. Minor surgical procedures generally feasible with precautions. No usual spontaneous bleeding in the absence of trauma. |
| Severe thrombocytopenia | 20 to 50 × 10⁹/L | Risk of spontaneous petechial purpura + mucosal bleeding (epistaxis + gingival bleeding + menorrhagia) + relative contraindication to invasive procedures + platelet transfusion if urgent surgical procedure |
| Critical thrombocytopenia | < 20 billion/L | Major spontaneous hemorrhagic risk + extensive petechial purpura + mucosal hemorrhage + risk of cerebral hemorrhage + platelet transfusion recommended if < 10 × 10⁹/L or if < 20 × 10⁹/L with active bleeding |
| Reactive thrombocytosis | 450 to 1,000 x 10⁹/L | Response to inflammatory process + infection + iron deficiency + asplenia → benign + no specific antiplatelet treatment required unless associated cardiovascular risk factors |
| Extreme thrombocytosis | 1,000 x 10⁹/L | Evoke a myeloproliferative neoplasm (essential thrombocythemia) + paradoxical risk of thrombosis AND hemorrhage (acquired von Willebrand syndrome with very high platelet count) + urgent hematology consultation |
Causes of thrombocytopenia
| Mechanism | Main causes | Biological and Clinical Characteristics |
|---|---|---|
| Peripheral destruction immune | Immune thrombocytopenic purpura (ITP) — most common cause of isolated thrombocytopenia in adults + auto-antibodies IgG anti-GPIIb/IIIa or anti-GPIb/IX → accelerated destruction of platelets by splenic macrophages + drug-induced ITP (heparin — HIT + quinine + trimethoprim-sulfamethoxazole) + systemic lupus erythematosus + antiphospholipid syndrome + pregnancy (gestational thrombocytopenia + pregnant ITP + HELLP) | Isolated thrombocytopenia (normal anemia and leukocytes) + increased megakaryocytes on bone marrow biopsy (compensatory medullary hyperreactivity) + anti-platelet antibodies in ITP (low sensitivity assay) + blood smear: large platelets (giant platelets) + no other abnormalities |
| Thrombotic Microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP—ADAMTS13 deficiency) + hemolytic uremic syndrome (HUS—E. coli O157:H7 or atypical HUS) + HELLP syndrome (pregnancy) + drug-induced MA T (quinine + ticlopidine + gemcitabine) + DIC (disseminated intravascular coagulation) | Thrombocytopenia + microangiopathic hemolytic anemia (schistocytes on smear ++ + elevated LDH + collapsed haptoglobin + negative Coombs) + acute kidney injury (HUS) + neurological signs (TTP) + therapeutic emergency (plasma exchange in TTP) |
| Hypersplenism (splenic sequestration) | Liver cirrhosis with portal hypertension (most common cause of hypersplenism) + lymphoid hemopathies with splenomegaly (chronic lymphoid leukemia + lymphomas) + storage diseases (Gaucher's disease) | Moderate thrombocytopenia (rarely < 50 × 10⁹/L) + often moderate pancytopenia (anemia + leukopenia + thrombocytopenia) + clinical and ultrasonographic splenomegaly + context of chronic liver disease or hematologic malignancy |
| Bone marrow failure | Bone marrow aplasia (pancytopenia + empty marrow) + acute leukemia (marrow infiltration by blasts) + myelodysplastic syndrome + bone marrow metastases + B12 or folate deficiency (dysthrombopoiesis) | Pancytopenia (simultaneous anemia + leukopenia + thrombocytopenia) + bone marrow aspirate and biopsy are essential + circulating blasts if acute leukemia |
| Cytotoxic or toxic drugs | Chemotherapies (platelet nadir 10 to 14 days after treatment) + alcohol (direct toxicity on megakaryocytes + associated folate deficiency) + valproate + certain antibiotics + linezolid | Temporal correlation with drug introduction + normalization upon discontinuation + in chemotherapy: predictable and transient thrombocytopenia occurring at the nadir of myelosuppression |
| Heparin-induced thrombocytopenia (HIT) | Antibodies against heparin-platelet factor 4 complex (PF4) → paradoxical platelet activation → paradoxical thrombocytopenia + arterial and venous thrombosis + occurring 5 to 10 days after heparin initiation (or earlier with recent prior exposure) | Platelet drop > 50% from baseline + heparin therapy (unfractionated heparin + LMWH) + high 4T score → anti-PF4 antibodies + immediate discontinuation of all heparin + alternative anticoagulant (argatroban + fondaparinux + bivalirudin) → hematology emergency due to serious thrombotic risk |
| EDTA-induced pseudothrombocytopenia | EDTA-dependent autoantibodies inducing in vitro platelet aggregation in EDTA tube (purple cap) → platelet aggregates are counted as leukocytes or not counted → artifactual thrombocytopenia | Blood smear: clumps of platelets (aggregates) → confirms the artifact + normal platelet count in citrate- or heparin-treated tubes → definitively rules out true thrombocytopenia + prevalence: 0.1 to 0.2% of the population + should be suspected in cases of asymptomatic thrombocytopenia with no other explanation |
ℹ️
The first step when thrombocytopenia is discovered on a blood test is to check the blood smear to rule out pseudothrombocytopenia related to EDTA (presence of platelet aggregates) and to look for schistocytes (red blood cell fragments) which indicate a thrombotic microangiopathy — a medical emergency requiring urgent plasma exchange in cases of TTP. A high-quality blood smear, read by an experienced technician or physician, is the most informative and least expensive complementary examination in hematology.
Immune thrombocytopenic purpura (ITP) — most frequent cause
- Definition: isolated immune thrombocytopenia with platelets < 100 × 10⁹/L + absence of other identifiable cause + diagnosis of exclusion + can be primary (idiopathic) or secondary (SLE + APS + HIV or HCV infection + medications + lymphoma)
- Clinical Presentation: Petechial purpura of the lower extremities + spontaneous ecchymoses + epistaxis + gingival bleeding + menorrhagia in women + rare but serious: cerebral hemorrhage (risk < 1 %, but monitor platelet levels < 10 × 10⁹/L)
- First-line treatment: corticosteroids (prednisone 1 mg/kg/day × 3 to 4 weeks with gradual tapering) + intravenous immunoglobulins (IVIG 1 g/kg × 2 days) if urgent response is necessary (active bleeding + urgent surgery) + eltrombopag or romiplostim (thrombopoietin receptor agonists) if corticosteroid-refractory or corticosteroid-dependent + rituximab + splenectomy for refractory chronic ITP
- Platelet targets by situation: Platelets > 20–30 × 10⁹/L if asymptomatic + > 50 × 10⁹/L before minor invasive procedure + > 80 × 10⁹/L before major surgery + > 100 × 10⁹/L before neurosurgery or lumbar puncture
Causes of thrombocytosis
| Type of thrombocytosis | Etiologies and mechanisms | Support |
|---|---|---|
| Reactive (secondary) thrombocytosis | The most common (80% of thrombocytosis cases) + causes: acute and chronic infections + inflammation (chronic inflammatory diseases—rheumatoid arthritis + IBD) + iron deficiency (very common—mechanism uncertain but well documented) + functional asplenia or post-splenectomy + response to surgical or traumatic stress + medications (G-CSF + epinephrine + vincristine) | Treatment of the underlying cause → normalization of platelets within weeks + no specific antiplatelet treatment required for reactive thrombocytosis + low thrombotic risk in reactive forms |
| Essential thrombocythemia (ET) | Clonal myeloproliferative disorder + JAK2 V617F mutation (55–60% of cases) + CALR mutation (25–30% of cases) + MPL (5 %) + autonomous platelet overproduction by abnormal megakaryocytes + platelet counts often > 600–800 × 10⁹/L + platelet functional abnormalities regardless of platelet count | Aspirin 100 mg/day for all patients at intermediate or high risk (history of thrombosis or hemorrhage + age > 60 years + JAK2 mutation) + cytoreduction (hydroxyurea + anagrelide) if high thrombotic risk + lifelong hematological monitoring + JAK2, CALR, MPL testing + blood smear |
| Other myeloproliferative neoplasms with thrombocytosis | Polycythemia Vera (PV) + Primary Myelofibrosis (PMF) + Chronic Myeloid Leukemia (CML) → possible thrombocytosis in each of these syndromes + clinical and cytogenetic context (Philadelphia chromosome for CML) allow for distinction | Hematological workup for diagnostic confirmation + molecular testing (BCR-ABL for CML + JAK2 + CALR + MPL for PV + ET + MF) + specific treatment according to type |
Situations requiring urgent medical attention
Call 911 or go to the emergency room immediately if thrombocytopenia is accompanied by a sudden, severe headache (cerebral hemorrhage), blurred vision or confusion (TTP or cerebral hemorrhage), uncontrollable heavy bleeding (massive mucosal hemorrhage), or signs of shock. Thrombocytopenia below 20 × 10⁹/L found on a workup requires medical evaluation the same day, even if the patient is asymptomatic.
The detection of schizocytes on a blood smear, along with thrombocytopenia and hemolytic anemia, constitutes an absolute hematologic emergency suggestive of thrombotic thrombocytopenic purpura (TTP)—treatment with plasma exchange must be initiated within 4 to 6 hours at a specialized hospital, as the mortality rate for untreated TTP exceeds 90% %.
For the interpretation of an abnormal platelet count, the prescription of complementary tests, and referral to hematology if necessary, Clinique Omicron offers medical consultations at its service points in Quebec and via telemedicine. To make an appointment, visit cliniqueomicron.ca.
Consult at Clinique Omicron
Clinique Omicron's specialized nurse practitioners (NPs) and physicians interpret abnormal platelet counts, order blood smears and appropriate etiological workups (hemostasis testing + autoimmune testing + infectious disease testing + bone marrow assessment as needed), initiate treatment for ITP, and refer patients to hematology for severe thrombocytopenia or thrombocytosis suggestive of a myeloproliferative neoplasm. Consultations are available at several service locations in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not substitute for medical or hematologist advice. Any thrombocytopenia below 50 × 10⁹/L or thrombocytosis above 800 × 10⁹/L requires immediate medical evaluation to determine the cause and initiate appropriate treatment.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.